Gilead Sciences | GILD - Selling And Administration Expenses



Gilead Sciences reported $1.36B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Agios Pharmaceuticals USD 45.87M 4.34M Jun/2025
ALKERMES USD 153.87M 17.83M Jun/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
Amgen USD 1.69B 4M Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Glaxosmithkline GBP 2.09B 609M Jun/2025
Incyte USD 331.02M 5.33M Jun/2025
J&J USD 5.89B 777M Jun/2025
Merck USD 2.63B 104M Jun/2025
Moderna USD 230M 18M Jun/2025
Neurocrine Biosciences USD 286.3M 9.8M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
PTC Therapeutics USD 85.26M 76.66M Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Sanofi EUR 2.63B 408M Jun/2025
Sarepta Therapeutics USD 69.89M 63.74M Jun/2025
United Therapeutics USD 212.5M 42.4M Jun/2025
Vertex Pharmaceuticals USD 424.6M 28.2M Jun/2025